Log in

CytRx Stock Price, Forecast & Analysis (OTCMKTS:CYTR)

$0.27
+0.01 (+3.92 %)
(As of 11/19/2019 09:06 AM ET)
Today's Range
$0.21
Now: $0.27
$0.28
50-Day Range
$0.26
MA: $0.31
$0.33
52-Week Range
$0.21
Now: $0.27
$0.78
Volume102,661 shs
Average Volume55,025 shs
Market Capitalization$8.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CYTR
CUSIPN/A
Phone310-826-5648

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$250,000.00
Book Value$0.61 per share

Profitability

Net Income$-12,710,000.00

Miscellaneous

Employees6
Market Cap$8.91 million
Next Earnings Date11/22/2019 (Estimated)
OptionableOptionable

Receive CYTR News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTR and its competitors with MarketBeat's FREE daily newsletter.


CytRx (OTCMKTS:CYTR) Frequently Asked Questions

What is CytRx's stock symbol?

CytRx trades on the OTCMKTS under the ticker symbol "CYTR."

When did CytRx's stock split? How did CytRx's stock split work?

CytRx shares reverse split on the morning of Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 31st 2017. An investor that had 100 shares of CytRx stock prior to the reverse split would have 17 shares after the split.

How were CytRx's earnings last quarter?

CytRx Co. (OTCMKTS:CYTR) announced its quarterly earnings results on Friday, August, 9th. The biotechnology company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.02. View CytRx's Earnings History.

When is CytRx's next earnings date?

CytRx is scheduled to release their next quarterly earnings announcement on Friday, November 22nd 2019. View Earnings Estimates for CytRx.

What price target have analysts set for CYTR?

1 brokerages have issued 1 year target prices for CytRx's stock. Their forecasts range from $5.00 to $5.00. On average, they expect CytRx's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,786.8% from the stock's current price. View Analyst Price Targets for CytRx.

What is the consensus analysts' recommendation for CytRx?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytRx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytRx.

Has CytRx been receiving favorable news coverage?

Media coverage about CYTR stock has been trending very negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CytRx earned a news sentiment score of -3.9 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for CytRx.

Who are some of CytRx's key competitors?

What other stocks do shareholders of CytRx own?

Who are CytRx's key executives?

CytRx's management team includes the folowing people:
  • Mr. Steven A. Kriegsman, Chairman & CEO (Age 77)
  • Mr. John Y. Caloz, Chief Financial Officer (Age 67)
  • Dr. Felix Kratz Ph.D., Sr. VP, Drug Devel. (Age 56)
  • Mr. Eric L. Curtis M.B.A., Pres & COO (Age 50)

How do I buy shares of CytRx?

Shares of CYTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CytRx's stock price today?

One share of CYTR stock can currently be purchased for approximately $0.27.

How big of a company is CytRx?

CytRx has a market capitalization of $8.91 million and generates $250,000.00 in revenue each year. The biotechnology company earns $-12,710,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. CytRx employs 6 workers across the globe.View Additional Information About CytRx.

What is CytRx's official website?

The official website for CytRx is http://www.cytrx.com/.

How can I contact CytRx?

CytRx's mailing address is 11726 SAN VICENTE BOULEVARD SUITE 650, LOS ANGELES CA, 90049. The biotechnology company can be reached via phone at 310-826-5648 or via email at [email protected]


MarketBeat Community Rating for CytRx (OTCMKTS CYTR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  326 (Vote Outperform)
Underperform Votes:  235 (Vote Underperform)
Total Votes:  561
MarketBeat's community ratings are surveys of what our community members think about CytRx and other stocks. Vote "Outperform" if you believe CYTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Featured Article: Earnings Reports

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel